Delivery Order SPE2DB20D2014-SPE2DB25FC24J
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,976.56 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count) on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $2,432.43 to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-count packaging) on August 19, 2025, with an ultimate completion date of August 20, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office...
- The Defense Logistics Agency awarded a $4.77K firm fixed price delivery order to AmerisourceBergen Drug Corp on June 26, 2025, for the supply of Veozah 45 mg tablets (30-count packages). This is a non-set-aside, competitively awarded contract with an ultimate completion date of June 27, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $1,038.28 to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-count) on July 23, 2025, with completion targeted for July 24, 2025. This firm fixed-price delivery order represents a small-value pharmaceutical transaction under a competitive award with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,470.52 to AmerisourceBergen Drug Corp for Veozah 45 mg tablets (30-unit supply), with an ultimate completion date of July 25, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,541.30 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-unit package) on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitive award utilized firm fixed pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $2,768.73 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count) on September 5, 2025, with an ultimate completion date of September 8, 2025. The contract is non-set-aside and competitively awarded, with performance to be completed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Veozah 45 mg tablets (30-count packages) under a firm fixed-price arrangement. The contract ceiling value is $6,509.38, with an ultimate completion date of July 31, 2025. This delivery order represents a non-set-aside, competitively awarded transaction executed through AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,502.99 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count packages) on September 9, 2025, with an ultimate completion date of September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value transaction typical of the agency's pharmaceutical procurement operations. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $5,292.12 to AmerisourceBergen Drug Corp for the supply of Veozah 45 mg tablets (30-count units) on August 11, 2025, with an ultimate completion date of August 12, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is classified as a child contract under AmerisourceBergen's broader pharmaceutical supply agreements with the federal government. The product will be delivered to the company's...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC24JDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,467.93 to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Veozah 45 mg tablets (30-count packages). This non-set-aside, competitively awarded contract employs firm fixed-price pricing and requires completion by June 18, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor serving federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a global pharmaceutical support vehicle enabling AmerisourceBergen to supply an expansive range of medications, medical devices, and healthcare commodities to support military healthcare programs worldwide. The company's demonstrated capability to fulfill federal medical procurement requirements through open competition, combined with its comprehensive product portfolio spanning specialty medications, brand-name and generic drugs, and specialized medical supplies, positions it as a critical vendor for Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 6/17/25 |